ASIA PACIFIC CRISPR MARKET FORECAST 2018-2026
KEY FINDINGS
The revenue generated by the Asia-Pacific CRISPR market is expected to catapult from $92 million in 2017 to $1725 million by 2026, at a CAGR of 38.86%. CRISPR majorly finds its applications in industries like agriculture and animal breeding for this region.
MARKET INSIGHTS
China, Japan, and India are some of the major markets contributing to the Asia-Pacific CRISPR market. The Japanese CRISPR market contributed the highest revenue share in 2017, but it is the South Korea market that is expected to progress with the highest CAGR over the forecast period. However, even though more and more research on GMOs is being performed in the Asia-Pacific region, people are still concerned about the undiscovered side effects and unanticipated adverse effects of the CRISPR technology on the environment. Also, possible misuse of CRISPR gene editing tools is another major factor hindering the market growth.
COMPETITIVE INSIGHTS
Intellia Therapeutics Inc, Caribou Biosciences Inc, Cellectis Bioresearch Sas, Integrated DNA Technologies (IDT), Crispr Therapeutics Ag,Genscript, Novartis International Ag, Editas Medicine, Transposagen Biopharmaceuticals Inc, Thermo Fisher Scientific, Sigma-Aldrich (Merck), Precision Biosciences and Horizon Discovery Plc are some of the established players in this market.
The revenue generated by the Asia-Pacific CRISPR market is expected to catapult from $92 million in 2017 to $1725 million by 2026, at a CAGR of 38.86%. CRISPR majorly finds its applications in industries like agriculture and animal breeding for this region.
MARKET INSIGHTS
China, Japan, and India are some of the major markets contributing to the Asia-Pacific CRISPR market. The Japanese CRISPR market contributed the highest revenue share in 2017, but it is the South Korea market that is expected to progress with the highest CAGR over the forecast period. However, even though more and more research on GMOs is being performed in the Asia-Pacific region, people are still concerned about the undiscovered side effects and unanticipated adverse effects of the CRISPR technology on the environment. Also, possible misuse of CRISPR gene editing tools is another major factor hindering the market growth.
COMPETITIVE INSIGHTS
Intellia Therapeutics Inc, Caribou Biosciences Inc, Cellectis Bioresearch Sas, Integrated DNA Technologies (IDT), Crispr Therapeutics Ag,Genscript, Novartis International Ag, Editas Medicine, Transposagen Biopharmaceuticals Inc, Thermo Fisher Scientific, Sigma-Aldrich (Merck), Precision Biosciences and Horizon Discovery Plc are some of the established players in this market.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. DESIGN TOOLS ARE GROWING AT A FASTER RATE IN TERMS OF PRODUCT
3.2.2. PHARMA COMPANIES ARE GROWING RAPIDLY
3.2.3. GENOME EDITING TO HOLD THE LARGEST SHARE
4. MARKET DETERMINANTS
4.1. DRIVERS
4.1.1. INCREASING DEMAND FOR DRUG DISCOVERY
4.1.2. LATE PREGNANCIES LEADING TO BIRTH DISORDERS
4.1.3. SYNTHETIC GENES LEAD THE WAY
4.1.4. AGING GENETIC DISORDERS
4.1.5. INVESTMENT IN PATH BREAKING RESEARCH TECHNOLOGY
4.1.6. CHANGING LIFESTYLES
4.2. RESTRAINTS
4.2.1. POSSIBLE MISUSE OF CRISPR GENE EDITING TOOL
4.2.2. LACK OF AWARENESS
4.3. OPPORTUNITIES
4.3.1. GENOME SURGERY TO REWRITE GENETIC DISORDERS
4.3.2. CLINICAL TRIALS IN ASIA
4.4. CHALLENGES
4.4.1. PROTECTION OF PATENT
4.4.2. ALTERNATE TECHNOLOGIES
4.4.3. LACK OF HEALTHCARE BUDGETS IN DEVELOPING COUNTRIES
5. MARKET SEGMENTATION
5.1. MARKET BY PRODUCT 2018-2026
5.1.1. DESIGN TOOLS
5.1.2. PLASMIDS AND VECTORS
5.1.3. CAS9 NUCLEASE AND GRNA
5.1.4. DELIVERY SYSTEM
5.2. MARKET BY END USER 2018-2026
5.2.1. BIOTECHNOLOGY FIRMS
5.2.2. PHARMACEUTICAL COMPANIES
5.2.3. ACADEMIC INSTITUTES
5.2.4. RESEARCH FOUNDATION
5.3. MARKET BY APPLICATION 2018-2026
5.3.1. GENOME EDITING
5.3.2. GENETIC ENGINEERING
5.3.3. GRNA DATABASE/GENE LIBRARY
5.3.4. CRISPR PLASMID
5.3.5. HUMAN STEM CELLS
5.3.6. GENETICALLY MODIFIED ORGANISMS/CROPS
5.3.7. CELL LINE ENGINEERING
6. KEY ANALYTICS
6.1. PORTER’S 5 FORCE MODEL
6.1.1. THREATS OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTES
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. MARKET ETYMOLOGY
6.3. SUPPLY CHAIN ANALYSIS
6.4. REGULATORY FRAMEWORK
6.5. VALUE CHAIN ANALYSIS
6.6. KEY BUYING CRITERIA
6.7. PATENT ANALYSIS
6.8. 360 DEGREE ANALYSIS
6.9. STRATEGIC RECOMMENDATION AND CONCLUSION
7. GEOGRAPHICAL ANALYSIS
7.1. ASIA PACIFIC (APAC)
7.1.1. INDIA
7.1.2. CHINA
7.1.3. JAPAN
7.1.4. SOUTH KOREA
7.1.5. REST OF APAC
8. COMPANY PROFILE
8.1. COMPETITIVE ANALYSIS
8.1.1. TOP 5 COMPANIES
8.1.2. MERGERS AND ACQUISITION
8.1.3. PARTNERSHIPS AND COLLABORATIONS
8.1.4. INNOVATIONS
8.1.5. VENTURE CAPITAL FUNDING
8.2. EDITAS MEDICINE
8.3. CRISPR THERAPEUTICS AG
8.4. HORIZON DISCOVERY PLC.
8.5. SIGMA-ALDRICH (MERCK)
8.6. GENSCRIPT
8.7. SANGAMO BIOSCIENCES INC.
8.8. LONZA GROUP AG
8.9. INTEGRATED DNA TECHNOLOGIES (IDT)
8.10. NEW ENGLAND BIOLABS INC
8.11. ORIGENE TECHNOLOGIES INC
8.12. TRANSPOSAGEN BIOPHARMACEUTICALS INC.
8.13. THERMO FISHER SCIENTIFIC
8.14. CARIBOU BIOSCIENCES INC.
8.15. PRECISION BIOSCIENCES
8.16. CELLECTIS BIORESEARCH SAS
8.17. INTELLIA THERAPEUTICS INC
8.18. NOVARTIS INTERNATIONAL AG
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. DESIGN TOOLS ARE GROWING AT A FASTER RATE IN TERMS OF PRODUCT
3.2.2. PHARMA COMPANIES ARE GROWING RAPIDLY
3.2.3. GENOME EDITING TO HOLD THE LARGEST SHARE
4. MARKET DETERMINANTS
4.1. DRIVERS
4.1.1. INCREASING DEMAND FOR DRUG DISCOVERY
4.1.2. LATE PREGNANCIES LEADING TO BIRTH DISORDERS
4.1.3. SYNTHETIC GENES LEAD THE WAY
4.1.4. AGING GENETIC DISORDERS
4.1.5. INVESTMENT IN PATH BREAKING RESEARCH TECHNOLOGY
4.1.6. CHANGING LIFESTYLES
4.2. RESTRAINTS
4.2.1. POSSIBLE MISUSE OF CRISPR GENE EDITING TOOL
4.2.2. LACK OF AWARENESS
4.3. OPPORTUNITIES
4.3.1. GENOME SURGERY TO REWRITE GENETIC DISORDERS
4.3.2. CLINICAL TRIALS IN ASIA
4.4. CHALLENGES
4.4.1. PROTECTION OF PATENT
4.4.2. ALTERNATE TECHNOLOGIES
4.4.3. LACK OF HEALTHCARE BUDGETS IN DEVELOPING COUNTRIES
5. MARKET SEGMENTATION
5.1. MARKET BY PRODUCT 2018-2026
5.1.1. DESIGN TOOLS
5.1.2. PLASMIDS AND VECTORS
5.1.3. CAS9 NUCLEASE AND GRNA
5.1.4. DELIVERY SYSTEM
5.2. MARKET BY END USER 2018-2026
5.2.1. BIOTECHNOLOGY FIRMS
5.2.2. PHARMACEUTICAL COMPANIES
5.2.3. ACADEMIC INSTITUTES
5.2.4. RESEARCH FOUNDATION
5.3. MARKET BY APPLICATION 2018-2026
5.3.1. GENOME EDITING
5.3.2. GENETIC ENGINEERING
5.3.3. GRNA DATABASE/GENE LIBRARY
5.3.4. CRISPR PLASMID
5.3.5. HUMAN STEM CELLS
5.3.6. GENETICALLY MODIFIED ORGANISMS/CROPS
5.3.7. CELL LINE ENGINEERING
6. KEY ANALYTICS
6.1. PORTER’S 5 FORCE MODEL
6.1.1. THREATS OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTES
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. MARKET ETYMOLOGY
6.3. SUPPLY CHAIN ANALYSIS
6.4. REGULATORY FRAMEWORK
6.5. VALUE CHAIN ANALYSIS
6.6. KEY BUYING CRITERIA
6.7. PATENT ANALYSIS
6.8. 360 DEGREE ANALYSIS
6.9. STRATEGIC RECOMMENDATION AND CONCLUSION
7. GEOGRAPHICAL ANALYSIS
7.1. ASIA PACIFIC (APAC)
7.1.1. INDIA
7.1.2. CHINA
7.1.3. JAPAN
7.1.4. SOUTH KOREA
7.1.5. REST OF APAC
8. COMPANY PROFILE
8.1. COMPETITIVE ANALYSIS
8.1.1. TOP 5 COMPANIES
8.1.2. MERGERS AND ACQUISITION
8.1.3. PARTNERSHIPS AND COLLABORATIONS
8.1.4. INNOVATIONS
8.1.5. VENTURE CAPITAL FUNDING
8.2. EDITAS MEDICINE
8.3. CRISPR THERAPEUTICS AG
8.4. HORIZON DISCOVERY PLC.
8.5. SIGMA-ALDRICH (MERCK)
8.6. GENSCRIPT
8.7. SANGAMO BIOSCIENCES INC.
8.8. LONZA GROUP AG
8.9. INTEGRATED DNA TECHNOLOGIES (IDT)
8.10. NEW ENGLAND BIOLABS INC
8.11. ORIGENE TECHNOLOGIES INC
8.12. TRANSPOSAGEN BIOPHARMACEUTICALS INC.
8.13. THERMO FISHER SCIENTIFIC
8.14. CARIBOU BIOSCIENCES INC.
8.15. PRECISION BIOSCIENCES
8.16. CELLECTIS BIORESEARCH SAS
8.17. INTELLIA THERAPEUTICS INC
8.18. NOVARTIS INTERNATIONAL AG
LIST OF TABLES
TABLE 1 ASIA PACIFIC CRISPR MARKET 2018-2026 ($ MILLIONS)
TABLE 2 RISING PUBLIC HEALTH AND LONG-TERM CARE EXPENDITURE OVER THE NEXT DECADES (%)
TABLE 3 MAJOR CONCERNS RELATED TO GENETIC ENGINEERING
TABLE 4 ASIA PACIFIC CRISPR MARKET IN PRODUCT MARKET SHARE 2018-2026 ($ MILLIONS)
TABLE 5 TOOLS NAME AND THEIR PROVIDERS
TABLE 6 ASIA PACIFIC CRISPR MARKET IN DESIGN TOOLS 2018-2026 ($ MILLIONS)
TABLE 7 ASIA PACIFIC CRISPR MARKET IN PLASMIDS AND VECTORS 2018-2026 ($ MILLIONS)
TABLE 8 ASIA PACIFIC CRISPR MARKET IN CAS9 NUCLEASE AND GRNA 2018-2026 ($ MILLIONS)
TABLE 9 ASIA PACIFIC CRISPR MARKET IN DELIVERY SYSTEM 2018-2026 ($ MILLIONS)
TABLE 10 ASIA PACIFIC CRISPR MARKET IN END USER 2018-2026 ($ MILLIONS)
TABLE 11 ASIA PACIFIC CRISPR MARKET IN BIOTECH FIRMS 2018-2026 ($ MILLION)
TABLE 12 ASIA PACIFIC CRISPR MARKET IN PHARMA COMPANIES 2018-2026 ($ MILLIONS)
TABLE 13 ASIA PACIFIC CRISPR MARKET IN ACADEMIC INSTITUTIONS 2018-2026 ($ MILLION)
TABLE 14 ASIA PACIFIC CRISPR MARKET IN RESEARCH FOUNDATION 2018-2026 ($ MILLIONS)
TABLE 15 ASIA PACIFIC CRISPR MARKET, BY APPLICATION 2018-2026 ($ MILLIONS)
TABLE 16 ASIA PACIFIC CRISPR MARKET IN GENOME EDITING 2018-2026 ($ MILLIONS)
TABLE 17 ASIA PACIFIC CRISPR MARKET IN GENETIC ENGINEERING 2018-2026 ($ MILLIONS)
TABLE 18 ASIA PACIFIC CRISPR MARKET IN GRNA DATABASE/GENE LIBRARY 2018-2026 ($ MILLIONS)
TABLE 19 ASIA PACIFIC CRISPR MARKET IN CRISPR PLASMID 2018-2026 ($ MILLIONS)
TABLE 20 ASIA PACIFIC CRISPR MARKET IN HUMAN STEM CELLS 2018-2026 ($ MILLIONS)
TABLE 21 ASIA PACIFIC CRISPR MARKET IN GENETICALLY MODIFIED ORGANISMS/CROPS 2018-2026 ($ MILLIONS)
TABLE 22 ASIA PACIFIC CRISPR MARKET IN CELL LINE ENGINEERING 2018-2026 ($ MILLIONS)
TABLE 23 ASIA PACIFIC CRISPER MARKET, 2018-2026 ($ MILLION)
TABLE 24 FUNDS ALLOCATED FOR RESEARCH ACTIVITIES IN BUDGET 2016
TABLE 25 APAC CRISPR MARKET 2018-2026 ($ MILLIONS)
TABLE 1 ASIA PACIFIC CRISPR MARKET 2018-2026 ($ MILLIONS)
TABLE 2 RISING PUBLIC HEALTH AND LONG-TERM CARE EXPENDITURE OVER THE NEXT DECADES (%)
TABLE 3 MAJOR CONCERNS RELATED TO GENETIC ENGINEERING
TABLE 4 ASIA PACIFIC CRISPR MARKET IN PRODUCT MARKET SHARE 2018-2026 ($ MILLIONS)
TABLE 5 TOOLS NAME AND THEIR PROVIDERS
TABLE 6 ASIA PACIFIC CRISPR MARKET IN DESIGN TOOLS 2018-2026 ($ MILLIONS)
TABLE 7 ASIA PACIFIC CRISPR MARKET IN PLASMIDS AND VECTORS 2018-2026 ($ MILLIONS)
TABLE 8 ASIA PACIFIC CRISPR MARKET IN CAS9 NUCLEASE AND GRNA 2018-2026 ($ MILLIONS)
TABLE 9 ASIA PACIFIC CRISPR MARKET IN DELIVERY SYSTEM 2018-2026 ($ MILLIONS)
TABLE 10 ASIA PACIFIC CRISPR MARKET IN END USER 2018-2026 ($ MILLIONS)
TABLE 11 ASIA PACIFIC CRISPR MARKET IN BIOTECH FIRMS 2018-2026 ($ MILLION)
TABLE 12 ASIA PACIFIC CRISPR MARKET IN PHARMA COMPANIES 2018-2026 ($ MILLIONS)
TABLE 13 ASIA PACIFIC CRISPR MARKET IN ACADEMIC INSTITUTIONS 2018-2026 ($ MILLION)
TABLE 14 ASIA PACIFIC CRISPR MARKET IN RESEARCH FOUNDATION 2018-2026 ($ MILLIONS)
TABLE 15 ASIA PACIFIC CRISPR MARKET, BY APPLICATION 2018-2026 ($ MILLIONS)
TABLE 16 ASIA PACIFIC CRISPR MARKET IN GENOME EDITING 2018-2026 ($ MILLIONS)
TABLE 17 ASIA PACIFIC CRISPR MARKET IN GENETIC ENGINEERING 2018-2026 ($ MILLIONS)
TABLE 18 ASIA PACIFIC CRISPR MARKET IN GRNA DATABASE/GENE LIBRARY 2018-2026 ($ MILLIONS)
TABLE 19 ASIA PACIFIC CRISPR MARKET IN CRISPR PLASMID 2018-2026 ($ MILLIONS)
TABLE 20 ASIA PACIFIC CRISPR MARKET IN HUMAN STEM CELLS 2018-2026 ($ MILLIONS)
TABLE 21 ASIA PACIFIC CRISPR MARKET IN GENETICALLY MODIFIED ORGANISMS/CROPS 2018-2026 ($ MILLIONS)
TABLE 22 ASIA PACIFIC CRISPR MARKET IN CELL LINE ENGINEERING 2018-2026 ($ MILLIONS)
TABLE 23 ASIA PACIFIC CRISPER MARKET, 2018-2026 ($ MILLION)
TABLE 24 FUNDS ALLOCATED FOR RESEARCH ACTIVITIES IN BUDGET 2016
TABLE 25 APAC CRISPR MARKET 2018-2026 ($ MILLIONS)
LIST OF FIGURES
FIGURE 1 FATALITIES INCREASING DUE TO LIFESTYLE ORIENTED DISEASES (IN THOUSAND)
FIGURE 2 REASON FOR OUTSOURCING DRUG DISCOVERY PROJECTS
FIGURE 3 ASIA PACIFIC CRISPR MARKET IN DESIGN TOOLS MARKET SHARE 2018-2026 ($ MILLIONS)
FIGURE 4 ASIA PACIFIC CRISPR MARKET IN PLASMIDS AND VECTORS 2018-2026 ($ MILLIONS)
FIGURE 5 ASIA PACIFIC CRISPR MARKET IN CAS9 NUCLEASE AND GRNA 2018-2026 ($ MILLIONS)
FIGURE 6 ASIA PACIFIC CRISPR MARKET IN DELIVERY SYSTEM 2018-2026 ($ MILLIONS)
FIGURE 7 ASIA PACIFIC CRISPR MARKET IN BIOTECH FIRMS 2018-2026 ($ MILLION)
FIGURE 8 ASIA PACIFIC CRISPR MARKET IN PHARMA COMPANIES 2018-2026 ($ MILLION)
FIGURE 9 ASIA PACIFIC CRISPR MARKET IN ACADEMIC INSTITUTIONS 2018-2026 ($ MILLION)
FIGURE 10 ASIA PACIFIC CRISPR MARKET IN RESEARCH FOUNDATION 2018-2026 ($ MILLIONS)
FIGURE 11 ASIA PACIFIC CRISPR MARKET IN GENOME EDITING 2018-2026 ($ MILLIONS)
FIGURE 12 ASIA PACIFIC CRISPR MARKET IN GENETIC ENGINEERING 2018-2026 ($ MILLIONS)
FIGURE 13 ASIA PACIFIC CRISPR MARKET IN GRNA DATABASE/GENE LIBRARY 2018-2026 ($ MILLIONS)
FIGURE 14 ASIA PACIFIC CRISPR MARKET IN CRISPR PLASMID 2018-2026 ($ MILLIONS)
FIGURE 15 ASIA PACIFIC CRISPR MARKET IN HUMAN STEM CELLS 2018-2026 ($ MILLIONS)
FIGURE 16 ASIA PACIFIC CRISPR MARKET IN GENETICALLY MODIFIED ORGANISMS/CROPS 2018-2026 ($ MILLIONS)
FIGURE 17 ASIA PACIFIC CRISPR MARKET IN CELL LINE ENGINEERING 2018-2026 ($ MILLIONS)
FIGURE 18 VALUE CHAIN ANALYSIS
FIGURE 19 ASIA PACIFIC CRISPR MARKET SHARE BY REGION, 2016
FIGURE 20 INDIA CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 21 CHINA CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 22 JAPAN CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 23 SOUTH KOREA CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 24 REST OF APAC CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 25 ROPAC CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 26 CRISPR MARKET COMPANIES SHARE 2016
COMPANIES MENTIONED
2. EDITAS MEDICINE
3. CRISPR THERAPEUTICS AG
4. HORIZON DISCOVERY PLC.
5. SIGMA-ALDRICH (MERCK)
6. GENSCRIPT
7. SANGAMO BIOSCIENCES INC.
8. LONZA GROUP AG
9. INTEGRATED DNA TECHNOLOGIES (IDT)
10. NEW ENGLAND BIOLABS INC
11. ORIGENE TECHNOLOGIES INC
12. TRANSPOSAGEN BIOPHARMACEUTICALS INC.
13. THERMO FISHER SCIENTIFIC
14. CARIBOU BIOSCIENCES INC.
15. PRECISION BIOSCIENCES
16. CELLECTIS BIORESEARCH SAS
17. INTELLIA THERAPEUTICS INC
18. NOVARTIS INTERNATIONAL AG
FIGURE 1 FATALITIES INCREASING DUE TO LIFESTYLE ORIENTED DISEASES (IN THOUSAND)
FIGURE 2 REASON FOR OUTSOURCING DRUG DISCOVERY PROJECTS
FIGURE 3 ASIA PACIFIC CRISPR MARKET IN DESIGN TOOLS MARKET SHARE 2018-2026 ($ MILLIONS)
FIGURE 4 ASIA PACIFIC CRISPR MARKET IN PLASMIDS AND VECTORS 2018-2026 ($ MILLIONS)
FIGURE 5 ASIA PACIFIC CRISPR MARKET IN CAS9 NUCLEASE AND GRNA 2018-2026 ($ MILLIONS)
FIGURE 6 ASIA PACIFIC CRISPR MARKET IN DELIVERY SYSTEM 2018-2026 ($ MILLIONS)
FIGURE 7 ASIA PACIFIC CRISPR MARKET IN BIOTECH FIRMS 2018-2026 ($ MILLION)
FIGURE 8 ASIA PACIFIC CRISPR MARKET IN PHARMA COMPANIES 2018-2026 ($ MILLION)
FIGURE 9 ASIA PACIFIC CRISPR MARKET IN ACADEMIC INSTITUTIONS 2018-2026 ($ MILLION)
FIGURE 10 ASIA PACIFIC CRISPR MARKET IN RESEARCH FOUNDATION 2018-2026 ($ MILLIONS)
FIGURE 11 ASIA PACIFIC CRISPR MARKET IN GENOME EDITING 2018-2026 ($ MILLIONS)
FIGURE 12 ASIA PACIFIC CRISPR MARKET IN GENETIC ENGINEERING 2018-2026 ($ MILLIONS)
FIGURE 13 ASIA PACIFIC CRISPR MARKET IN GRNA DATABASE/GENE LIBRARY 2018-2026 ($ MILLIONS)
FIGURE 14 ASIA PACIFIC CRISPR MARKET IN CRISPR PLASMID 2018-2026 ($ MILLIONS)
FIGURE 15 ASIA PACIFIC CRISPR MARKET IN HUMAN STEM CELLS 2018-2026 ($ MILLIONS)
FIGURE 16 ASIA PACIFIC CRISPR MARKET IN GENETICALLY MODIFIED ORGANISMS/CROPS 2018-2026 ($ MILLIONS)
FIGURE 17 ASIA PACIFIC CRISPR MARKET IN CELL LINE ENGINEERING 2018-2026 ($ MILLIONS)
FIGURE 18 VALUE CHAIN ANALYSIS
FIGURE 19 ASIA PACIFIC CRISPR MARKET SHARE BY REGION, 2016
FIGURE 20 INDIA CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 21 CHINA CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 22 JAPAN CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 23 SOUTH KOREA CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 24 REST OF APAC CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 25 ROPAC CRISPR MARKET 2018-2026 ($ MILLION)
FIGURE 26 CRISPR MARKET COMPANIES SHARE 2016
COMPANIES MENTIONED
2. EDITAS MEDICINE
3. CRISPR THERAPEUTICS AG
4. HORIZON DISCOVERY PLC.
5. SIGMA-ALDRICH (MERCK)
6. GENSCRIPT
7. SANGAMO BIOSCIENCES INC.
8. LONZA GROUP AG
9. INTEGRATED DNA TECHNOLOGIES (IDT)
10. NEW ENGLAND BIOLABS INC
11. ORIGENE TECHNOLOGIES INC
12. TRANSPOSAGEN BIOPHARMACEUTICALS INC.
13. THERMO FISHER SCIENTIFIC
14. CARIBOU BIOSCIENCES INC.
15. PRECISION BIOSCIENCES
16. CELLECTIS BIORESEARCH SAS
17. INTELLIA THERAPEUTICS INC
18. NOVARTIS INTERNATIONAL AG
